JP4838140B2 - 発作性脳発射を評価するための免疫吸着血液検査 - Google Patents
発作性脳発射を評価するための免疫吸着血液検査 Download PDFInfo
- Publication number
- JP4838140B2 JP4838140B2 JP2006539691A JP2006539691A JP4838140B2 JP 4838140 B2 JP4838140 B2 JP 4838140B2 JP 2006539691 A JP2006539691 A JP 2006539691A JP 2006539691 A JP2006539691 A JP 2006539691A JP 4838140 B2 JP4838140 B2 JP 4838140B2
- Authority
- JP
- Japan
- Prior art keywords
- glur1
- epilepsy
- antibody
- seizure
- seizures
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000010304 firing Methods 0.000 title claims description 24
- 210000004556 brain Anatomy 0.000 title abstract description 46
- 230000001314 paroxysmal effect Effects 0.000 title abstract description 18
- 239000003547 immunosorbent Substances 0.000 title abstract description 9
- 238000009534 blood test Methods 0.000 title description 4
- 206010010904 Convulsion Diseases 0.000 claims abstract description 121
- 238000000034 method Methods 0.000 claims abstract description 60
- 239000012634 fragment Substances 0.000 claims abstract description 40
- 239000012472 biological sample Substances 0.000 claims abstract description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 70
- 210000004369 blood Anatomy 0.000 claims description 18
- 239000008280 blood Substances 0.000 claims description 18
- 239000013060 biological fluid Substances 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 14
- 230000002776 aggregation Effects 0.000 claims description 11
- 238000004220 aggregation Methods 0.000 claims description 9
- 239000000523 sample Substances 0.000 claims description 8
- 230000008859 change Effects 0.000 claims description 6
- 239000007790 solid phase Substances 0.000 claims description 3
- 230000004931 aggregating effect Effects 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 abstract description 72
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 15
- 241000282414 Homo sapiens Species 0.000 abstract description 14
- 238000011282 treatment Methods 0.000 abstract description 13
- 238000002560 therapeutic procedure Methods 0.000 abstract description 10
- 239000000203 mixture Substances 0.000 abstract description 5
- 208000012902 Nervous system disease Diseases 0.000 abstract description 4
- 208000015114 central nervous system disease Diseases 0.000 abstract description 4
- 230000002490 cerebral effect Effects 0.000 abstract description 2
- 230000002082 anti-convulsion Effects 0.000 abstract 1
- 239000004816 latex Substances 0.000 description 34
- 229920000126 latex Polymers 0.000 description 34
- 206010036790 Productive cough Diseases 0.000 description 33
- 208000024794 sputum Diseases 0.000 description 33
- 210000003802 sputum Anatomy 0.000 description 32
- 238000012360 testing method Methods 0.000 description 29
- 102000004196 processed proteins & peptides Human genes 0.000 description 26
- 238000003556 assay Methods 0.000 description 22
- 238000003745 diagnosis Methods 0.000 description 20
- 239000000427 antigen Substances 0.000 description 17
- 102000036639 antigens Human genes 0.000 description 17
- 108091007433 antigens Proteins 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 230000035945 sensitivity Effects 0.000 description 16
- 239000001961 anticonvulsive agent Substances 0.000 description 15
- 238000003018 immunoassay Methods 0.000 description 15
- 208000011580 syndromic disease Diseases 0.000 description 15
- 150000001413 amino acids Chemical class 0.000 description 14
- 238000002965 ELISA Methods 0.000 description 12
- 125000003275 alpha amino acid group Chemical group 0.000 description 12
- 239000000090 biomarker Substances 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- 229920001184 polypeptide Polymers 0.000 description 11
- 108090000078 AMPA Receptors Proteins 0.000 description 10
- 102000003678 AMPA Receptors Human genes 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000002245 particle Substances 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 230000004520 agglutination Effects 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 210000002381 plasma Anatomy 0.000 description 9
- 206010026749 Mania Diseases 0.000 description 8
- 230000002159 abnormal effect Effects 0.000 description 8
- 229960003965 antiepileptics Drugs 0.000 description 8
- 230000000890 antigenic effect Effects 0.000 description 8
- 208000014617 hemorrhoid Diseases 0.000 description 8
- 230000009885 systemic effect Effects 0.000 description 8
- 102000018899 Glutamate Receptors Human genes 0.000 description 7
- 108010027915 Glutamate Receptors Proteins 0.000 description 7
- 208000006011 Stroke Diseases 0.000 description 7
- 230000001773 anti-convulsant effect Effects 0.000 description 7
- 239000011324 bead Substances 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000000926 neurological effect Effects 0.000 description 7
- 108010005456 AMPA 4 glutamate receptor ionotropic Proteins 0.000 description 6
- 102100030668 Glutamate receptor 4 Human genes 0.000 description 6
- 230000005856 abnormality Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 210000004408 hybridoma Anatomy 0.000 description 6
- 206010040954 Skin wrinkling Diseases 0.000 description 5
- 208000003443 Unconsciousness Diseases 0.000 description 5
- 239000012491 analyte Substances 0.000 description 5
- 229940125681 anticonvulsant agent Drugs 0.000 description 5
- 238000011088 calibration curve Methods 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 206010042772 syncope Diseases 0.000 description 5
- 230000001256 tonic effect Effects 0.000 description 5
- 230000037303 wrinkles Effects 0.000 description 5
- 208000024827 Alzheimer disease Diseases 0.000 description 4
- 206010013654 Drug abuse Diseases 0.000 description 4
- 102000004310 Ion Channels Human genes 0.000 description 4
- 108090000862 Ion Channels Proteins 0.000 description 4
- 201000009906 Meningitis Diseases 0.000 description 4
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 4
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 4
- 208000030886 Traumatic Brain injury Diseases 0.000 description 4
- 208000029028 brain injury Diseases 0.000 description 4
- 238000002591 computed tomography Methods 0.000 description 4
- 230000036461 convulsion Effects 0.000 description 4
- 230000009260 cross reactivity Effects 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 208000020016 psychiatric disease Diseases 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000011117 substance-related disease Diseases 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 241000239290 Araneae Species 0.000 description 3
- 208000008035 Back Pain Diseases 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 238000009007 Diagnostic Kit Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 206010027202 Meningitis bacterial Diseases 0.000 description 3
- 208000025966 Neurological disease Diseases 0.000 description 3
- 206010061334 Partial seizures Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000001467 acupuncture Methods 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 206010003074 arachnoiditis Diseases 0.000 description 3
- 201000009904 bacterial meningitis Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 206010014599 encephalitis Diseases 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- -1 kits Substances 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 206010025135 lupus erythematosus Diseases 0.000 description 3
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 241000557626 Corvus corax Species 0.000 description 2
- 208000008930 Low Back Pain Diseases 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- 208000019022 Mood disease Diseases 0.000 description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
- 206010029350 Neurotoxicity Diseases 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 206010058895 Psychogenic seizure Diseases 0.000 description 2
- 206010042464 Suicide attempt Diseases 0.000 description 2
- 206010044221 Toxic encephalopathy Diseases 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 238000005054 agglomeration Methods 0.000 description 2
- 238000007818 agglutination assay Methods 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 206010008129 cerebral palsy Diseases 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000002566 clonic effect Effects 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 231100000189 neurotoxic Toxicity 0.000 description 2
- 230000002887 neurotoxic effect Effects 0.000 description 2
- 231100000228 neurotoxicity Toxicity 0.000 description 2
- 230000007135 neurotoxicity Effects 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 229940124272 protein stabilizer Drugs 0.000 description 2
- 230000001107 psychogenic effect Effects 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical class NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 101001074427 Bacillus subtilis (strain 168) Polyketide synthase PksJ Proteins 0.000 description 1
- 101001074418 Bacillus subtilis (strain 168) Polyketide synthase PksL Proteins 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 102000004631 Calcineurin Human genes 0.000 description 1
- 108010042955 Calcineurin Proteins 0.000 description 1
- 102000019025 Calcium-Calmodulin-Dependent Protein Kinases Human genes 0.000 description 1
- 108010026870 Calcium-Calmodulin-Dependent Protein Kinases Proteins 0.000 description 1
- 102000007590 Calpain Human genes 0.000 description 1
- 108010032088 Calpain Proteins 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 206010012559 Developmental delay Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 206010013647 Drowning Diseases 0.000 description 1
- 208000001654 Drug Resistant Epilepsy Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 101000803786 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) Conidial yellow pigment biosynthesis polyketide synthase Proteins 0.000 description 1
- 101000701349 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) Putative sterigmatocystin biosynthesis polyketide synthase Proteins 0.000 description 1
- 206010014612 Encephalitis viral Diseases 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000004866 Hashish Substances 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000015371 Mandibular injury Diseases 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028347 Muscle twitching Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 208000037158 Partial Epilepsies Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 201000011252 Phenylketonuria Diseases 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101100244562 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) oprD gene Proteins 0.000 description 1
- 208000004974 Rolandic Epilepsy Diseases 0.000 description 1
- 102100029437 Serine/threonine-protein kinase A-Raf Human genes 0.000 description 1
- 101000730455 Serratia sp. (strain ATCC 39006) Beta-ketoacyl synthase PigJ Proteins 0.000 description 1
- 101000691656 Streptomyces venezuelae Narbonolide/10-deoxymethynolide synthase PikA1, modules 1 and 2 Proteins 0.000 description 1
- 101000691655 Streptomyces venezuelae Narbonolide/10-deoxymethynolide synthase PikA2, modules 3 and 4 Proteins 0.000 description 1
- 101000691658 Streptomyces venezuelae Narbonolide/10-deoxymethynolide synthase PikA3, module 5 Proteins 0.000 description 1
- 101001125873 Streptomyces venezuelae Narbonolide/10-deoxymethynolide synthase PikA4, module 6 Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000005978 brain dysfunction Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000028502 clonic seizure Diseases 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 108700023159 delta Opioid Receptors Proteins 0.000 description 1
- 102000048124 delta Opioid Receptors Human genes 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 102000021057 glutamate binding proteins Human genes 0.000 description 1
- 108091011212 glutamate binding proteins Proteins 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000001339 gustatory effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000011551 log transformation method Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 108010091748 peptide A Proteins 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000008786 sensory perception of smell Effects 0.000 description 1
- 210000002265 sensory receptor cell Anatomy 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 201000008914 temporal lobe epilepsy Diseases 0.000 description 1
- 238000011191 terminal modification Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000013464 vaginal disease Diseases 0.000 description 1
- 201000002498 viral encephalitis Diseases 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2857—Seizure disorders; Epilepsy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Addiction (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51767103P | 2003-11-06 | 2003-11-06 | |
| US60/517,671 | 2003-11-06 | ||
| PCT/US2004/037088 WO2005046442A2 (en) | 2003-11-06 | 2004-11-08 | Immunosorbent tests for assessing paroxysmal cerebral discharges |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007517188A JP2007517188A (ja) | 2007-06-28 |
| JP2007517188A5 JP2007517188A5 (enExample) | 2007-12-27 |
| JP4838140B2 true JP4838140B2 (ja) | 2011-12-14 |
Family
ID=34590180
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006539691A Expired - Fee Related JP4838140B2 (ja) | 2003-11-06 | 2004-11-08 | 発作性脳発射を評価するための免疫吸着血液検査 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7820398B2 (enExample) |
| EP (1) | EP1689288B1 (enExample) |
| JP (1) | JP4838140B2 (enExample) |
| CN (1) | CN1954211A (enExample) |
| AT (1) | ATE465412T1 (enExample) |
| AU (1) | AU2004288717A1 (enExample) |
| CA (1) | CA2585876A1 (enExample) |
| DE (1) | DE602004026767D1 (enExample) |
| EA (1) | EA200600920A1 (enExample) |
| WO (1) | WO2005046442A2 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6896872B2 (en) * | 2001-06-27 | 2005-05-24 | Svetlana A. Dambinova | Rapid multiple panel of biomarkers in laboratory blood tests for TIA/stroke |
| US20060257943A1 (en) * | 2005-01-25 | 2006-11-16 | Cis Biotech, Inc. | Ischemic biomarkers and their use to predict adverse neurological events from surgery |
| WO2006135893A2 (en) * | 2005-06-13 | 2006-12-21 | Cis Biotech, Inc. | Methods for diagnosing and treating cerebrovascular events based on nr2 peptides |
| US8536115B2 (en) | 2006-08-31 | 2013-09-17 | Centre For Addiction And Mental Health | Compositions and methods for modulating AMPA receptor-mediated excitotoxicity |
| WO2013102264A1 (en) * | 2012-01-04 | 2013-07-11 | Centre For Addiction And Mental Health | Compositions and methods for modulating ampa receptor-mediated excitotoxicity |
| US10610861B2 (en) | 2012-12-17 | 2020-04-07 | Accellix Ltd. | Systems, compositions and methods for detecting a biological condition |
| WO2014097286A1 (en) | 2012-12-17 | 2014-06-26 | Leukodx, Ltd. | Systems and methods for determining a chemical state |
| US9759722B2 (en) * | 2012-12-17 | 2017-09-12 | Leukodx Ltd. | Systems and methods for determining a chemical state |
| EP2863231A1 (en) * | 2013-10-17 | 2015-04-22 | Institut D'Investigaciones Biomédiques August Pi i Sunyer | Diagnostic method for detecting a GABA(A) related autoimmune disease and related subject-matter |
| US10194829B2 (en) | 2015-07-07 | 2019-02-05 | Q Bio, Inc. | Fast scanning based on magnetic resonance history |
| US9958521B2 (en) | 2015-07-07 | 2018-05-01 | Q Bio, Inc. | Field-invariant quantitative magnetic-resonance signatures |
| US9665734B2 (en) | 2015-09-12 | 2017-05-30 | Q Bio, Inc. | Uniform-frequency records with obscured context |
| US10964412B2 (en) | 2015-10-20 | 2021-03-30 | Q Bio, Inc. | Population-based medical rules via anonymous sharing |
| US10359486B2 (en) | 2016-04-03 | 2019-07-23 | Q Bio, Inc. | Rapid determination of a relaxation time |
| US10222441B2 (en) | 2016-04-03 | 2019-03-05 | Q Bio, Inc. | Tensor field mapping |
| WO2018144044A1 (en) * | 2017-02-03 | 2018-08-09 | Q Bio, Inc. | lTERATIVE MEDICAL TESTING OF BIOLOGICAL SAMPLES |
| US11650195B2 (en) | 2017-02-03 | 2023-05-16 | Q Bio, Inc. | Iterative medical testing of biological samples |
| US10936180B2 (en) | 2017-03-16 | 2021-03-02 | Q Bio, Inc. | User interface for medical information |
| US11360166B2 (en) | 2019-02-15 | 2022-06-14 | Q Bio, Inc | Tensor field mapping with magnetostatic constraint |
| US11354586B2 (en) | 2019-02-15 | 2022-06-07 | Q Bio, Inc. | Model parameter determination using a predictive model |
| CN113631924A (zh) | 2019-05-24 | 2021-11-09 | 富士瑞必欧株式会社 | 甲状腺球蛋白的测定方法和测定试剂 |
| US12320880B2 (en) | 2019-09-27 | 2025-06-03 | Q Bio, Inc. | Maxwell parallel imaging |
| CN114514427A (zh) | 2019-09-27 | 2022-05-17 | 富士瑞必欧株式会社 | 乙型肝炎病毒核心相关抗原的免疫测定和用于其的试剂盒 |
| WO2021062154A1 (en) | 2019-09-27 | 2021-04-01 | Q Bio, Inc. | Maxwell parallel imaging |
| US11614509B2 (en) | 2019-09-27 | 2023-03-28 | Q Bio, Inc. | Maxwell parallel imaging |
| CN115335700A (zh) | 2020-03-31 | 2022-11-11 | 富士瑞必欧株式会社 | 血中β淀粉样蛋白的免疫测定方法及用于该方法的试剂盒 |
| CN117616277A (zh) | 2021-08-06 | 2024-02-27 | 株式会社先端生命科学研究所 | 甲状腺球蛋白的免疫检测及用于其的试剂盒 |
| US11614508B1 (en) | 2021-10-25 | 2023-03-28 | Q Bio, Inc. | Sparse representation of measurements |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4879289A (en) * | 1988-05-24 | 1989-11-07 | Marion Laboratories, Inc. | Method of ameliorating epileptic seizures |
| EP0497884B1 (en) * | 1989-10-27 | 2004-04-28 | The Salk Institute For Biological Studies | Glutamate receptor compositions and methods |
| DE69128642T2 (de) | 1991-06-26 | 1998-08-06 | Dies Ooo | Immunadsorbens zur diagnose von epilepsie und der risikogruppe |
| WO1994006345A2 (en) | 1992-09-11 | 1994-03-31 | Dambinova Svetlana Alexandrovn | Immunosorbent for use in the diagnosis of neuro-psychological disorders, and use thereof |
| RU2112243C1 (ru) | 1995-11-29 | 1998-05-27 | Светлана Александровна Дамбинова | Набор "па-тест" для диагностики неврологических заболеваний |
| US6896872B2 (en) * | 2001-06-27 | 2005-05-24 | Svetlana A. Dambinova | Rapid multiple panel of biomarkers in laboratory blood tests for TIA/stroke |
| US20050233390A1 (en) * | 2003-04-09 | 2005-10-20 | Allen John W | Device including a proteinaceous factor, a recombinant proteinaceous factor, and a nucleotide sequence encoding the proteinaceous factor |
| US20060257943A1 (en) * | 2005-01-25 | 2006-11-16 | Cis Biotech, Inc. | Ischemic biomarkers and their use to predict adverse neurological events from surgery |
-
2004
- 2004-11-08 CN CNA2004800399514A patent/CN1954211A/zh active Pending
- 2004-11-08 DE DE602004026767T patent/DE602004026767D1/de not_active Expired - Lifetime
- 2004-11-08 AU AU2004288717A patent/AU2004288717A1/en not_active Abandoned
- 2004-11-08 US US10/983,845 patent/US7820398B2/en not_active Expired - Fee Related
- 2004-11-08 CA CA002585876A patent/CA2585876A1/en not_active Abandoned
- 2004-11-08 EP EP04818645A patent/EP1689288B1/en not_active Expired - Lifetime
- 2004-11-08 AT AT04818645T patent/ATE465412T1/de not_active IP Right Cessation
- 2004-11-08 WO PCT/US2004/037088 patent/WO2005046442A2/en not_active Ceased
- 2004-11-08 EA EA200600920A patent/EA200600920A1/ru unknown
- 2004-11-08 JP JP2006539691A patent/JP4838140B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20050181466A1 (en) | 2005-08-18 |
| ATE465412T1 (de) | 2010-05-15 |
| WO2005046442A2 (en) | 2005-05-26 |
| EP1689288A4 (en) | 2007-09-26 |
| AU2004288717A2 (en) | 2005-05-26 |
| AU2004288717A1 (en) | 2005-05-26 |
| US7820398B2 (en) | 2010-10-26 |
| CN1954211A (zh) | 2007-04-25 |
| EA200600920A1 (ru) | 2007-04-27 |
| DE602004026767D1 (de) | 2010-06-02 |
| JP2007517188A (ja) | 2007-06-28 |
| CA2585876A1 (en) | 2005-05-26 |
| WO2005046442A3 (en) | 2006-12-07 |
| EP1689288B1 (en) | 2010-04-21 |
| EP1689288A2 (en) | 2006-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4838140B2 (ja) | 発作性脳発射を評価するための免疫吸着血液検査 | |
| AU717198B2 (en) | Quantitation of p97 to diagnose and monitor Alzheimer's disease | |
| Singer et al. | Antibodies against human putamen in children with Tourette syndrome | |
| US20240361342A1 (en) | Lateral flow immunoassay method of simultaneously detecting hemoglobin s, hemoglobin c, and hemoglobin a in newborns, infants, children, and adults | |
| KR20040015168A (ko) | 알츠하이머 치매의 차별적 진단 방법과 진단 장치 | |
| US20070134738A1 (en) | Methods for detecting deficient cellular membrane tightly bound magnesium for disease diagnoses | |
| WO2021157634A1 (ja) | タウオパチーおよび認知症関連疾患の判定薬および判定方法 | |
| RU2435165C2 (ru) | Биомаркеры ишемии и их применение для прогнозирования неблагоприятных неврологических последствий хирургической операции | |
| US8084225B2 (en) | Methods for diagnosing cerebrovascular events based on NR2 peptides | |
| EP2924437B1 (en) | Method for detecting neurological disease accompanied by inflammation and/or demyelination | |
| JP7106810B2 (ja) | 新規肺がんマーカー | |
| JPWO2002037105A1 (ja) | 精神分裂病の診断薬キット | |
| JPWO2016136991A1 (ja) | 唾液中マーカータンパク質を用いた低栄養状態の判定方法、及びそれに使用する診断薬 | |
| WO2020051617A1 (en) | Method for diagnosing a liver disease | |
| WO2019111797A1 (ja) | 筋疾患の診断のためのバイオマーカー |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071108 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20071108 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100302 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20100304 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100601 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100608 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100902 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101130 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110225 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110304 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110531 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110830 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110929 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20141007 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4838140 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |